Mirati Therapeutics (NASDAQ:MRTX) reported Q4 EPS of ($3.51), $0.14 worse than the analyst estimate of ($3.37). Revenue for the quarter came in at $930 thousand versus the consensus estimate of $2.44 million.
Mirati Therapeutics (NASDAQ:MRTX) reported Q4 EPS of ($3.51), $0.14 worse than the analyst estimate of ($3.37). Revenue for the quarter came in at $930 thousand versus the consensus estimate of $2.44 million.